Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $215.4 million.

  • Regenxbio's Short-term Investments rose 832.82% to $215.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.4 million, marking a year-over-year increase of 832.82%. This contributed to the annual value of $177.2 million for FY2024, which is 2640.86% down from last year.
  • As of Q3 2025, Regenxbio's Short-term Investments stood at $215.4 million, which was up 832.82% from $243.7 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Short-term Investments peaked at $281.6 million during Q2 2022, and registered a low of $111.5 million during Q3 2021.
  • Moreover, its 5-year median value for Short-term Investments was $225.7 million (2024), whereas its average is $207.4 million.
  • Per our database at Business Quant, Regenxbio's Short-term Investments soared by 13931.33% in 2022 and then plummeted by 3896.86% in 2025.
  • Quarter analysis of 5 years shows Regenxbio's Short-term Investments stood at $112.2 million in 2021, then soared by 138.52% to $267.7 million in 2022, then dropped by 10.07% to $240.7 million in 2023, then dropped by 26.41% to $177.2 million in 2024, then grew by 21.59% to $215.4 million in 2025.
  • Its last three reported values are $215.4 million in Q3 2025, $243.7 million for Q2 2025, and $137.8 million during Q1 2025.